OTCMKTS:SBLOF Shin Nippon Biomedical Laboratories (SBLOF) Stock Price, News & Analysis $9.36 0.00 (0.00%) As of 08/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Shin Nippon Biomedical Laboratories Stock (OTCMKTS:SBLOF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SBLOF alerts:Sign Up Key Stats Today's Range$9.36▼$9.3650-Day Range$9.36▼$9.3652-Week Range$9.36▼$9.51VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Shin Nippon Biomedical Laboratories, Ltd. is a specialist contract research organization offering comprehensive nonclinical services to support early‐stage drug development. The company’s core activities include safety pharmacology, toxicology, pharmacokinetics, bioanalysis and ADME studies conducted under stringent GLP and quality assurance standards. Founded in 1991 and headquartered in Kagoshima, Japan, Shin Nippon Biomedical Laboratories operates multiple research facilities across Japan. These sites are equipped for rodent and non‐rodent studies and house advanced analytical laboratories, allowing the company to address a wide array of preclinical testing needs for pharmaceutical, biotechnology and agrochemical clients. Leveraging experienced scientific teams and state‐of‐the‐art infrastructure, Shin Nippon Biomedical Laboratories designs customized study protocols to generate reliable safety and efficacy data. The company’s services span from exploratory toxicology and dose‐range finding to pivotal GLP studies necessary for regulatory submissions in major markets. Shin Nippon Biomedical Laboratories serves both domestic and international biopharmaceutical customers, maintaining strategic partnerships to extend its global footprint. By adhering to global regulatory guidelines and emphasizing data integrity, the company aims to accelerate drug candidate evaluation and facilitate smoother transitions into clinical development.AI Generated. May Contain Errors. Read More Receive SBLOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shin Nippon Biomedical Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address SBLOF Stock News HeadlinesShin Nippon Biomedical 1Q Net Y260.00M Vs Net Y122.00MAugust 5, 2025 | marketwatch.comShin Nippon Biomedical Laboratories Reports Mixed Financial Results for Q1 2025August 5, 2025 | msn.comTurn $1K into $50K with This DeFi Gem$70 billion in 341 days: The fastest ETF in US history If you missed getting in early with the traditional players, there's still ONE way to capitalize on this institutional flood of money…August 16 at 2:00 AM | Crypto 101 Media (Ad)SBLOF Shin Nippon Biomedical Laboratories, Ltd. - Seeking AlphaJuly 3, 2025 | seekingalpha.comShin Nippon Biomed Lab (2395) - Investing.com UKJune 28, 2025 | uk.investing.comShin Nippon Biomedical Laboratories Corrects Financial Results for FY 2025May 16, 2025 | tipranks.comShin Nippon Biomedical FY Net Y4.92B Vs Net Y5.53BMay 8, 2025 | marketwatch.comShin Nippon Biomedical Reports Revenue Growth Amid Profit DeclineMay 7, 2025 | tipranks.comSee More Headlines SBLOF Stock Analysis - Frequently Asked Questions How have SBLOF shares performed this year? Shin Nippon Biomedical Laboratories' stock was trading at $9.82 on January 1st, 2025. Since then, SBLOF shares have decreased by 4.7% and is now trading at $9.36. How do I buy shares of Shin Nippon Biomedical Laboratories? Shares of SBLOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolOTCMKTS:SBLOF CIKN/A Webwww.snbl.co.jp Phone81-3-5565-5001FaxN/AEmployees1,344Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:SBLOF) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shin Nippon Biomedical Laboratories, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shin Nippon Biomedical Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.